602 related articles for article (PubMed ID: 18566819)
1. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
[TBL] [Abstract][Full Text] [Related]
2. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.
Mosconi L; Tsui WH; De Santi S; Li J; Rusinek H; Convit A; Li Y; Boppana M; de Leon MJ
Neurology; 2005 Jun; 64(11):1860-7. PubMed ID: 15955934
[TBL] [Abstract][Full Text] [Related]
3. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
[TBL] [Abstract][Full Text] [Related]
4. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
Kemppainen NM; Aalto S; Wilson IA; Någren K; Helin S; Brück A; Oikonen V; Kailajärvi M; Scheinin M; Viitanen M; Parkkola R; Rinne JO
Neurology; 2007 May; 68(19):1603-6. PubMed ID: 17485647
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
Ossenkoppele R; Tolboom N; Foster-Dingley JC; Adriaanse SF; Boellaard R; Yaqub M; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):990-1000. PubMed ID: 22441582
[TBL] [Abstract][Full Text] [Related]
6. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
[TBL] [Abstract][Full Text] [Related]
7. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
8. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
[TBL] [Abstract][Full Text] [Related]
10. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.
Mosconi L; Rinne JO; Tsui WH; Murray J; Li Y; Glodzik L; McHugh P; Williams S; Cummings M; Pirraglia E; Goldsmith SJ; Vallabhajosula S; Scheinin N; Viljanen T; Någren K; de Leon MJ
Neurobiol Aging; 2013 Jan; 34(1):22-34. PubMed ID: 22503001
[TBL] [Abstract][Full Text] [Related]
11. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.
Devanand DP; Mikhno A; Pelton GH; Cuasay K; Pradhaban G; Dileep Kumar JS; Upton N; Lai R; Gunn RN; Libri V; Liu X; van Heertum R; Mann JJ; Parsey RV
J Geriatr Psychiatry Neurol; 2010 Sep; 23(3):185-98. PubMed ID: 20430977
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
[TBL] [Abstract][Full Text] [Related]
13. Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.
Ito K; Shimano Y; Imabayashi E; Nakata Y; Omachi Y; Sato N; Arima K; Matsuda H
Int J Geriatr Psychiatry; 2014 Oct; 29(10):1079-86. PubMed ID: 24687634
[TBL] [Abstract][Full Text] [Related]
14. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
[TBL] [Abstract][Full Text] [Related]
15. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment.
Brück A; Virta JR; Koivunen J; Koikkalainen J; Scheinin NM; Helenius H; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1567-72. PubMed ID: 23801168
[TBL] [Abstract][Full Text] [Related]
16. Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.
Furukawa K; Okamura N; Tashiro M; Waragai M; Furumoto S; Iwata R; Yanai K; Kudo Y; Arai H
J Neurol; 2010 May; 257(5):721-7. PubMed ID: 19946781
[TBL] [Abstract][Full Text] [Related]
17. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
18. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
Hatashita S; Yamasaki H
PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 18F-FDG and PiB PET in cognitive impairment.
Lowe VJ; Kemp BJ; Jack CR; Senjem M; Weigand S; Shiung M; Smith G; Knopman D; Boeve B; Mullan B; Petersen RC
J Nucl Med; 2009 Jun; 50(6):878-86. PubMed ID: 19443597
[TBL] [Abstract][Full Text] [Related]
20. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
